To compare experimental canine pulmonary thromboembolism (PTE) treatment effects among domestic recombinant singlechain urokinase-type plasminogen activator (scu-PA), recombinant tissue plasminogen activator (rt-PA), and heparin, we injected autologous blood clots into 19 dogs. Those dogs were divided into 3 groups randomly: (1) scu-PA group (n ¼ 6), (2) rt-PA group (n ¼ 6), and (3) heparin group (n ¼ 7). The measurement of hemodynamics and pulmonary angiography was, respectively, carried out at the time spots of preemboli and postemboli, 2 hours and 3 hours after treatment. Results: (1) An obvious increase in mean pulmonary arterial pressure (mPAP) from preemboli (P < .01) and a decrease in cardiac output (CO; P < .01) after blood clot injection.
Introduction
Thrombolytic therapy is the first-line treatment for patients with high-risk pulmonary embolism (PE) presenting with cardiogenic shock and/or persistent arterial hypotension and may be considered in selected patients with intermediaterisk PE. 1 Satisfactory hemodynamic results have been obtained with streptokinase, urokinase (UK), recombinant tissue plasminogen activator (rt-PA), and reteplase. 1, 2 Some new fibrin-specific thrombolytic agents such as recombinant single-chain urokinase-type plasminogen activator (scu-PA) can be alternatives.
Single-chain urokinase-type plasminogen activator (or named pro-UK) was originally discovered in urine. 3 It is a precursor of UK (or named 2-chain urokinase-type plasminogen activator, tcu-PA), and several laboratory and animal studies have already identified that scu-PA is more effective and fibrin-selective than UK. [4] [5] [6] [7] Subsequently, scu-PA has been widely used in acute myocardial infarction [8] [9] [10] and ischemic stroke. 11, 12 However, there has been limited study of scu-PA on pulmonary thromboembolism (PTE).
In this study, we injected autologous clot into femoral vein to set up canine acute PTE model and compared the changes in hemodynamic parameters, pulmonary angiography before and after blood clot injection. Then, we compared the experimental canine PTE treatment effects among domestic recombinant scu-PA, rt-PA, and heparin. A quantitative evaluating method of the canine pulmonary artery angiography was also used in the study.
Methods
After animal research committee approval, 19 adult mongrel dogs, not stick to male and female, were anesthetized with intravenous pentobarbital (30 mg/kg), endotracheal intubated, and made to breathe room air in a supine position. 4, 13 We inserted into the left femoral an arterial catheter, which was used to measure the mean blood pressure (mBP) and heart rate (HR). A 7.5F sheath (Arrow International Inc., PA, USA) was placed into the right femoral vein to draw venous blood and alternately a 7F Swan-Ganz catheter (Arrow International) and a 6F pigtail catheter (Cordis Corporation, NJ, USA) was held.
Hemodynamic parameters of mean pulmonary arterial pressure (mPAP), cardiac output (CO), pulmonary arterial wedge pressure (PAWP), and central venous pressure (CVP) were obtained from the thermistor-tipped, flow-directed Swan-Ganz catheter that was connected with the monitor (HPM1165A, Hewlett-Packard Company, CA, USA). After that, the catheter was pulled out, and the pigtail catheter was inserted via the right femoral vein sheath immediately to perform pulmonary angiography.
Preparation of Canine PTE Model
Forty milliliters of blood, which was drawn for the formation of autologous clot, was loaded into 5 glass test tubes. The length of the tube was 8 cm and the diameter was 1.2 cm. After heating in the water bath at 37 C for 4 hours, the clot turned to a gelatinous cylinder about 3 to 5 cm in length and 0.6 to 0.9 cm in diameter. For the clot shorter than 4 cm, we sheared it in 2 segments of equal length and cut each in another 2 parts and then cut each of the 4 segments into 2 pieces lengthwise, so we got 2 Â 2 Â 2 ¼ 8 small clots. For the clot longer than 4 cm, we sheared it in 3 equal segments and did the same work as on the <4 cm ones and we got 3 Â 2 Â 2 ¼ 12 small clots. Excluding some necessary wastes, we got about 8 to 12 small clots of 1 Â 0.5 Â 0.5 cm from each original big clot. All the clots (40-60 small clots) were put into five 20 mL injectors with saline, and the clots suspended in the saline. After the baseline measurements were obtained, all the autologous clots were injected slowly via the 7.5F sheath in right femoral vein for a total time period of approximately more than 30 minutes with a 5-minute pause between each injector. After the last clot was injected, the model needed to stabilize for half an hour.
Protocol
About 1 hour after the first clot was injected, all the dogs received heparin (Changzhou Pharmaceutical Factory, Jiangsu, China) 100 U/kg intravenous bolus injection. Subsequently, the 3 groups were treated differently. The 19 dogs were randomized to one of the following treatments: (1) scu-PA group (n ¼ 6): received scu-PA 1 mg/kg (0.25 mg/kg bolus injection followed by 0.75 mg/kg infusion for more than 1 hour), 7 donated from Tasly Pharmaceutical Co Ltd, Tianjin, China);
(2) rt-PA group (n ¼ 6): received rt-PA 1.5 mg/kg (Boehringer Ingelheim Shanghai Pharmaceuticals Co Ltd, Shanghai, China) infusion for more than 45 minutes 13 ; and (3) heparin group (n ¼ 7): 10 U/kg per hour infusion during the whole course of the experiment. After the scu-PA and rt-PA infusions were over, the scu-PA group and rt-PA group again were given heparin infusion. According to Tasly, manufacturer of the scu-PA, the recombinant scu-PA was produced in the Chinese Hamster Ovary (CHO) cells; the percentage of the single chain in the drug is higher than 98%, identified by S-2444 method. We used Random Allocation Table ( RAT) Generator Version 2.00 software to create a list ensuring the grouping was random.
Hemodynamic measurements (HR, mBP, mPAP, CO, PAWP, and CVP) and pulmonary angiography were taken at the following times: baseline, prior to clot injection; following embolization, immediately prior to treatment; and at 2 and 3 hours after the onset of drug infusion. Glucose-saline solution was infused at a speed of 50 to 100 mL/h to maintain the stability of internal environment.
Assessment of Pulmonary Thrombolysis
All the pulmonary angiography were reviewed in random order by 2 radiologists, who had experience in reading canine pulmonary angiography and were ignorant of treatment used. They assessed the severity of embolism by an ''modified Miller Index,'' which was a combination of Miller Index 14 and selected pulmonary angiography evaluation, 15 as described below.
Modified Miller Index (Figure 1 ): the dog is regarded as having 4 lobar vessels on the right pulmonary artery and 3 on the left. If the lobar vessels as well as the distal segmental vessels are completely normal, the score is zero. If the lobar vessels are normal, but partial distal segmental vessels are still filled with significant clot, the score is 1 point. If emboli remained in all segmental vessels and/or the lobar vessel, the score is 2. Therefore, the involvement by emboli of all the branches of the right pulmonary artery scores a maximum of 8 and of the left pulmonary artery a maximum of 6 points. In addition, the effect of embolism on pulmonary artery flow is scored as follows: each lung is divided into 3 zones (upper, middle, and lower) and flow in each zone is assessed as absent (3 points), severely reduced (2 points), mildly reduced (1 point), or normal (zero). The maximum score for reduction in pulmonary artery flow is therefore 9 points for each lung (total 18), and the maximum possible score for flow reduction and involvement of arteries by embolism is 32 points. The higher the score the higher the grade of severity of PTE. 
Statistical Analysis
The parameters of hemodynamic changes of embolization were analyzed by a paired t test. In each group, we used repeatedmeasures analysis of variance (ANOVA) to test for differences among measurement stages. If the ANOVA F statistic was significant (P < .05), a multiple comparison test (Student-Newman-Keuls) detected the differing stages. The differences among the 3 groups were compared by a 1-way ANOVA. Values are reported as mean + SD. Chi-square test was used for categorical variables. The results of quantitative pulmonary angiography and bleeding adverse effect were showed in a descriptive way. Table 1 illustrated the background of dogs and baseline data of hemodynamic parameters in each group. There were no statistical differences among each group. Table 2 illustrated the mean hemodynamic values before and after embolization in all 19 dogs. Embolization caused a marked increase in mPAP (P < .001) and a corresponding decrease in CO (P < .01). Mean BP, HR, and CVP remained constant. Pulmonary arterial wedge pressure had an increase of 0.95 mm Hg but without a significance (P > .05). Figure 2 plotted mean (+SD) value and illustrated the effects of emboli and treatment on mPAP. It noted the marked increase in mPAP with embolization and the subsequent decrease in scu-PA and rt-PA groups. Note that mPAP did not decrease in the heparin group (P > .05). Compared with postembolization values, mPAP decreased significantly (P < .01) in the 2 thrombolysis groups 2 and 3 hours, respectively, after onset of treatment. Compared among groups, mPAP was significantly lower in scu-PA and rt-PA than heparin group after treatment. However, there was no statistical difference between scu-PA and rt-PA groups. Figure 3 illustrated effects of embolization and treatment on CO. In all groups, CO tended to decline. However, compared with postembolization values, there was no significant decrease in scu-PA and rt-PA groups after treatment. However, CO had significantly decreased (P < .05) in the heparin group 3 hours after onset of treatment. Intergroup comparisons revealed no differences among groups over time. There were no inner or intergroup statistic differences in HR, mBP, PAWP, or CVP.
Results
The sign of emboli can be seen in pulmonary angiography after the injection of autologous blood clot (Figure 4 ), and the score was higher than 7 in every dog of postembolization. There were 13 dogs with the score higher than 18 postemboli and that meant serious thrombolization. After 2 and 3 hours' thrombolysis by scu-PA, most vessels got reperfused, and the angiography was near normal ( Figure 5 ). The change of pulmonary angiography was similar in rt-PA group. However, in heparin group, there was no obvious improvement. Table 3 illustrated the score changing in different groups at different times. After 2 hours' treatment, the scores decreased by over 50% in 5 of 6 dogs in scu-PA group, 4 of 6 dogs in rt-PA group but none in heparin group. After 3 hours' treatment, the scores of all the 6 dogs in scu-PA group, 4 of 6 dogs in rt-PA group, and none in heparin group fell by as high as 50%.
There were in total 3 cases of subcutaneous hematoma in scu-PA group, 3 cases in rt-PA group, and 1 in heparin group. The size of hemotoma ranged from 2 Â 2 cm to 7 Â 7 cm. All the hemotomas were found around the femoral arterial catheters. None of the dogs had macroscopic hematuria, black stool, or bleeding in endotracheal intubation. 
Discussion
This study compared experimental canine PTE treatment effects among domestic recombinant scu-PA, rt-PA, and heparin. The PTE modal was based on the method of Prewitt research group, 13, 16 who drew 120 mL blood that was kept in the water bath for 1.5 hours for formation of autologous clot. In our study, we reduced the volume to 40 mL blood to make the dog safer and less vulnerable to the damage impact of the operation. After the injection of autologous clot, mPAP increased by 10 mm Hg. That caused a significant increase in pulmonary vascular resistances (PVRs), which resulted in pulmonary hypertension and an acute rise in right ventricular (RV) afterload. The combination of impaired RV systolic function and tricuspid regurgitation decreased RV output, and this combined with a fall in left ventricular (LV) compliance, reduced LV filling (preload) and stroke volume. A significant fall in stroke volume may, in turn, lead to a decrease in CO, hypotension, and systemic hypoperfusion. 17 Thus, we found the CO declined by 0.7 L/min after clot injection. In this study, mBP had a mild decrease. The change of hymodynamics was similar to previous studies.
The stability of the canine model has been proved by radiological lung scan. 13, 16 We documented the PTE by the ''gold standard'' method of pulmonary angiography. However, the evaluation of full pulmonary angiography for dogs is still difficult. We combined ''Miller Index'' and the method of selected pulmonary angiography evaluation to form a ''modified Miller Index.'' After clot injection, the score of 68% of the dogs was more than 18, which simulated a clinical multiple occlusions of vessels. This method may be a constructive way to evaluate canine pulmonary angiography.
As a second-generation thrombolytic agent, scu-PA is a zymogen form of UK with a highly selective mode of action under physiological conditions. [4] [5] [6] Previous study has already confirmed that intravenous bolus injection of scu-PA appeared to be equipotent to an infusion over 60 minutes for both coronary and venous thrombolysis. The dose of 1 mg/kg was more effective than 0.5 mg/kg 7 for dogs. Werier et al 13 also identified that 1.5 mg/kg of rt-PA over 45 minutes approached the maximum thrombolytic effect in canine PTE model. Therefore, we compared the effects of 2 thrombolytic agents with an ideal dosage. After thrombolysis by scu-PA and rt-PA, mPAP decreased significantly and CO remained constant. On the contrary, mPAP did not improve much in heparin group after onset of treatment, and CO deteriorated 3 hours later. It may be explained by the fact that continuous occlusion of pulmonary artery leads to the long-time overloading of the RV. Because the heart is contained within the pericardium, RV pressure and volume overload cause a shift of the interventricular septum, hence reducing both LV chamber size and compliance. So, rapid relief of pulmonary arterial occlusion is very important to massive PTE. 1, 17 Thrombolysis of rt-PA on massive PTE has been well established. In addition, there was no hemodynamic difference between scu-PA and rt-PA after onset of treatment in our study. Meanwhile, decrease in pulmonary angiography scoring of 2 thrombolytic groups was higher than that of heparin group. The bleeding adverse effect was more serious in the 2 thrombolytic groups than heparin. This may be related to the brevity of time between the use of thrombolytic agents and heparin. Admittedly, fibrinogen and plasminogen can reflect the degree of fibrinolysis; the existing researches have already revealed how fibrinogen and plasminogen would change after the use of scu-PA. Hence, those 2 parameters were not mentioned and measured in our research.
The first pilot study of saruplase (scu-PA) on PTE patients, which was documented in 1998, showed rapid hemodynamic and angiographic improvement, 18 but there was no control group in that study. After that, there have been few related researches of scu-PA on PTE. Now, the injection recombinant scu-PA freeze-dried powder is a new biological product that is under complete intellectual property right in China, with the production cost of about US$36 per dose. That would be affordable to more common patients.
In this canine model, we concluded that the effects of domestic recombinant scu-PA in experimental PTE resembled that of rt-PA in terms of improving hemodynamics and angiography, better than heparin. It may be a new choice for patients with massive and submassive PTE, but further animal and clinical experiments are to be made.
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